Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report | Zendy

Kaps Leonard | Zendy; Labenz Christian | Zendy; Grimm Daniel | Zendy; Schwarting Andreas | Zendy; Galle Peter R. | Zendy; Schreiner Oliver | Zendy

Open Access

Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report

Author(s) -

Kaps Leonard,

Labenz Christian,

Grimm Daniel,

Schwarting Andreas,

Galle Peter R.,

Schreiner Oliver

Publication year - 2020

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.3307

Subject(s) - anakinra , cytokine storm , medicine , ards , cytokine release syndrome , immunosuppression , covid-19 , cytokine , sepsis , receptor antagonist , immunology , antagonist , intensive care medicine , receptor , virology , lung , infectious disease (medical specialty) , disease , outbreak

The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID‐19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research